These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Involvement of the macrophage low density lipoprotein receptor-binding domains in the uptake of oxidized low density lipoprotein. Keidar S; Brook GJ; Rosenblat M; Fuhrman B; Dankner G; Aviram M Arterioscler Thromb; 1992 Apr; 12(4):484-93. PubMed ID: 1373074 [TBL] [Abstract][Full Text] [Related]
23. Foam cell formation containing lipid droplets enriched with free cholesterol by hyperlipidemic serum. Mori M; Itabe H; Higashi Y; Fujimoto Y; Shiomi M; Yoshizumi M; Ouchi Y; Takano T J Lipid Res; 2001 Nov; 42(11):1771-81. PubMed ID: 11714846 [TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody against protein-bound glutathione: use of glutathione conjugate of acrolein-modified proteins as an immunogen. Furuhata A; Honda K; Shibata T; Chikazawa M; Kawai Y; Shibata N; Uchida K Chem Res Toxicol; 2012 Jul; 25(7):1393-401. PubMed ID: 22716076 [TBL] [Abstract][Full Text] [Related]
25. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Shaw PX; Hörkkö S; Tsimikas S; Chang MK; Palinski W; Silverman GJ; Chen PP; Witztum JL Arterioscler Thromb Vasc Biol; 2001 Aug; 21(8):1333-9. PubMed ID: 11498462 [TBL] [Abstract][Full Text] [Related]
27. Specific interaction of oxidized low-density lipoprotein with macrophage-derived foam cells isolated from rabbit atherosclerotic lesions. de Vries HE; Buchner B; van Berkel TJ; Kuiper J Arterioscler Thromb Vasc Biol; 1999 Mar; 19(3):638-45. PubMed ID: 10073968 [TBL] [Abstract][Full Text] [Related]
28. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Boyd HC; Gown AM; Wolfbauer G; Chait A Am J Pathol; 1989 Nov; 135(5):815-25. PubMed ID: 2683796 [TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Torzewski M; Klouche M; Hock J; Messner M; Dorweiler B; Torzewski J; Gabbert HE; Bhakdi S Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):369-78. PubMed ID: 9514405 [TBL] [Abstract][Full Text] [Related]
31. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843 [TBL] [Abstract][Full Text] [Related]
32. Nitric oxide inhibition of lipoxygenase-dependent liposome and low-density lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivatives. Rubbo H; Parthasarathy S; Barnes S; Kirk M; Kalyanaraman B; Freeman BA Arch Biochem Biophys; 1995 Dec; 324(1):15-25. PubMed ID: 7503550 [TBL] [Abstract][Full Text] [Related]
33. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Palinski W; Ylä-Herttuala S; Rosenfeld ME; Butler SW; Socher SA; Parthasarathy S; Curtiss LK; Witztum JL Arteriosclerosis; 1990; 10(3):325-35. PubMed ID: 1693068 [TBL] [Abstract][Full Text] [Related]
34. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. Friedman P; Horkko S; Steinberg D; Witztum JL; Dennis EA J Biol Chem; 2002 Mar; 277(9):7010-20. PubMed ID: 11744722 [TBL] [Abstract][Full Text] [Related]
35. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. Podrez EA; Poliakov E; Shen Z; Zhang R; Deng Y; Sun M; Finton PJ; Shan L; Febbraio M; Hajjar DP; Silverstein RL; Hoff HF; Salomon RG; Hazen SL J Biol Chem; 2002 Oct; 277(41):38517-23. PubMed ID: 12145296 [TBL] [Abstract][Full Text] [Related]
36. Stimulation with a monoclonal antibody (mAb4E4) of scavenger receptor-mediated uptake of chemically modified low density lipoproteins by THP-1-derived macrophages enhances foam cell generation. Holvoet P; Perez G; Bernar H; Brouwers E; Vanloo B; Rosseneu M; Collen D J Clin Invest; 1994 Jan; 93(1):89-98. PubMed ID: 8282826 [TBL] [Abstract][Full Text] [Related]
37. Generation of a polyclonal antibody against lipid peroxide-modified proteins. Kim JG; Sabbagh F; Santanam N; Wilcox JN; Medford RM; Parthasarathy S Free Radic Biol Med; 1997; 23(2):251-9. PubMed ID: 9199887 [TBL] [Abstract][Full Text] [Related]
38. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Vaarala O; Puurunen M; Lukka M; Alfthan G; Leirisalo-Repo M; Aho K; Palosuo T Clin Exp Immunol; 1996 May; 104(2):269-74. PubMed ID: 8625519 [TBL] [Abstract][Full Text] [Related]
39. Characterization of a specific monoclonal antibody 9F5-3a and the development of assay system for oxidized HDL. Nakajima T; Sakagishi Y; Katahira T; Nagata A; Kuwae T; Nakamura H; Inoue I; Takahashi K; Katayama S; Komoda T Biochem Biophys Res Commun; 1995 Dec; 217(2):407-11. PubMed ID: 7503715 [TBL] [Abstract][Full Text] [Related]
40. Circulating autoantibodies recognizing peroxidase-oxidized low density lipoprotein. Evidence for new antigenic epitopes formed in vivo independently from lipid peroxidation. Seccia M; Albano E; Maggi E; Bellomo G Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):134-40. PubMed ID: 9012648 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]